bluebird bio Inc (NASDAQ:BLUE) – Investment analysts at Leerink Swann boosted their FY2017 earnings estimates for bluebird bio in a report issued on Thursday. Leerink Swann analyst M. Schmidt now expects that the biotechnology company will post earnings of ($6.86) per share for the year, up from their previous forecast of ($6.90). Leerink Swann currently has a “Market Perform” rating and a $194.00 price target on the stock. Leerink Swann also issued estimates for bluebird bio’s Q4 2017 earnings at ($1.72) EPS, Q2 2018 earnings at ($1.78) EPS, Q3 2018 earnings at ($1.86) EPS, Q4 2018 earnings at ($1.94) EPS, FY2018 earnings at ($7.25) EPS, FY2019 earnings at ($7.95) EPS and FY2020 earnings at ($5.33) EPS.
BLUE has been the topic of a number of other reports. Morgan Stanley raised bluebird bio from an “underweight” rating to an “equal weight” rating in a research report on Friday, November 3rd. Evercore ISI raised bluebird bio from an “in-line” rating to an “outperform” rating and set a $102.00 target price on the stock in a research report on Monday, October 16th. Maxim Group set a $170.00 target price on bluebird bio and gave the stock a “buy” rating in a research report on Friday, November 17th. CIBC began coverage on bluebird bio in a research report on Thursday, December 21st. They set a “market perform” rating on the stock. Finally, BidaskClub raised bluebird bio from a “buy” rating to a “strong-buy” rating in a research report on Friday. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $159.05.
bluebird bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.05). The company had revenue of $7.71 million for the quarter, compared to analyst estimates of $8.47 million. bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. The firm’s revenue for the quarter was up 397.4% on a year-over-year basis. During the same period last year, the firm earned ($2.07) earnings per share.
In related news, insider David Davidson sold 3,522 shares of the company’s stock in a transaction on Monday, January 8th. The stock was sold at an average price of $173.61, for a total transaction of $611,454.42. Following the transaction, the insider now directly owns 13,959 shares of the company’s stock, valued at $2,423,421.99. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Nick Leschly sold 2,127 shares of the company’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $145.17, for a total value of $308,776.59. Following the transaction, the chief executive officer now directly owns 257,486 shares in the company, valued at $37,379,242.62. The disclosure for this sale can be found here. Insiders have sold 201,045 shares of company stock worth $35,817,777 over the last three months. 3.90% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of BLUE. Ladenburg Thalmann Financial Services Inc. boosted its stake in shares of bluebird bio by 454.2% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock worth $136,000 after acquiring an additional 813 shares in the last quarter. QS Investors LLC boosted its stake in shares of bluebird bio by 70.7% during the 2nd quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock worth $127,000 after acquiring an additional 500 shares in the last quarter. Biondo Investment Advisors LLC bought a new stake in shares of bluebird bio during the 3rd quarter worth about $203,000. World Asset Management Inc bought a new stake in shares of bluebird bio during the 3rd quarter worth about $230,000. Finally, Comerica Bank bought a new stake in shares of bluebird bio during the 3rd quarter worth about $242,000.
COPYRIGHT VIOLATION NOTICE: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2018/01/29/bluebird-bio-inc-blue-expected-to-earn-fy2017-earnings-of-6-86-per-share.html.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.